SARS-CoV-2 (2019-nCoV) Research - Latest Insights & Products
The ongoing coronavirus disease-19 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus-2, SARS-CoV-2 (or 2019-nCoV), a β-coronavirus that has crossed species barriers to infect humans [1, 2]. A similar disease was provoked in the past by two other β-coronaviruses, SARS-CoV in 2002  and MERS-CoV in 2012 . SARS-CoV-2 exhibits a high infectious rate and provokes a wide-array of symptoms (no clinical signs, mild, acute, or life-threatening ). Today it represents a real burden not only for human health, but also for civil societies, and the global economy.
This is the third outbreak due to a highly-pathogenic β-coronavirus in only two decades. This points towards the tremendous need to acquire in-depth knowledge of the virus infectious cycle among species, the cellular pathways involved in the viral replication, and the mounting of innate and adaptive immune responses. Answers to these fundamental questions shall help in the design of safe and efficient therapeutics, as well as prophylactic vaccines.
InvivoGen offers an expanding set of tools to foster research on SARS-CoV-2 infection and immune responses:
Viral RdRp Inhibitor
JAK/STAT Signaling Inhibitors
Endosomal Acidification Inhibitors
- Bafilomycin A1
InvivoGen’s products are for research use only, and not for clinical or veterinary use.
Reviews on COVID-19
1. Zhu, N. et al. 2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382, 727-733.
3. Drosten C. et al., 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:1967-1976.
4. De Groot R.J. et al., 2013. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): announcement of the coronavirus study group. J Virol. 87(14):7790-7792.